
Relaunching SUFF ON

Surfactant Or Not

Recruitment Restart
04 July 2022

Multicentre, open-label, randomised controlled trial of early surfactant therapy versus expectant management in late preterm and early term infants with respiratory distress



- 34⁺⁰ 38⁺⁶ weeks gestation
- ≤ 24 hours old
- Respiratory distress
- $FiO_2 \ge 0.3$ and < 0.45 needed to maintain $SaO_2 \ge 92\%$ OR
- Clinically significant work of breathing, regardless of $\mathsf{FiO}_{\!_{2}}$
- Clinical decision to provide non-invasive respiratory support

Early surfactant therapy

· Incidence of severe respiratory failure, defined as:

• Written parental informed consent

Exclusion criteria

- Major structural or chromosomal anomalies
- No realistic prospect of survival
- Prior intubation and/or surfactant administration
- Known or suspected hypoxic ischaemic encephalopathy

Expectant management

- Congenital abnormality of the upper or lower respiratory tract
- Known or suspected neuromuscular disorder

If you are interested in taking part as a site or for more info, please contact
SurfON Study Team.

- **U** 01865 289 437/738
- surfon@npeu.ox.ac.uk
- www.npeu.ox.ac.uk/surfon
- - NPEUOxford

- sustained (≥ 30 minutes) requirement for FiO₂ ≥ 0.45 to maintain oxygen saturations (SaO₂) ≥ 92%

Randomisation 1:1 allocation ratio

OR

Primary Outcomes (from trial entry to hospital discharge home)
 Length of infant's hospital stay after birth, defined as the number of days from birth to discharge home

For further details please refer to the study Protocol.

FUNDED BY





This study is funded by the National Institute for Health and Care Research (NIHR) [Health Technology Assessment (HTA) (project reference 17/89/07)]. The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care.





Not for display in an area accessible by the patients or public